RxDoctor Payments Data

Victoria Garcia Albea, NP

Nurse Practitioner · Stoneham, MANPI 1770632036

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,645 of the $31,067 with a category attached, or 85.8%. 10 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 47.2% of the total. 2025 is the largest year on record at $16,739, more than ten times the $730 reported in 2021. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,067in general payments, 2019–2025

Across 48 payments — averaging $647.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$15K
  • Sanofi$7K
  • Eli Lilly$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • LEO Pharma Inc.$1K
  • UCB, Inc.$1K
  • plus $2K from 4 others

What the payments were for

  • Consulting fees$26,64586%
  • Travel & lodging$3,18910%
  • Food & beverage$9843%
  • Education$2501%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,067 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$51,900
Medicare patients
362
Services billed
1,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$406,837
Dupixent PenDupilumab59$281,851
Dupixent SyringeDupilumab18$111,774
JubliaEfinaconazole11$14,052
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc64$2,891
Minoxidil239$2,666
Spironolactone117$2,265
Hydroxychloroquine Sulfate34$2,135
Pimecrolimus14$1,745
Tacrolimus11$1,697
Ketoconazole90$1,432
Fluorouracil20$1,263
Azelaic Acid12$829
Metronidazole16$827
Triamcinolone Acetonide53$733

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Stoneham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →